133 related articles for article (PubMed ID: 2410519)
1. [Clinical value of immunotherapy for gynecological cancer by BRM (biological response modifier)].
Akiya K; Negishi Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):1025-9. PubMed ID: 2410519
[No Abstract] [Full Text] [Related]
2. [Immunotherapy today. II. Immunostimulating therapy].
D'Amelio R
Riv Med Aeronaut Spaz; 1978; 41(1):75-114. PubMed ID: 93770
[No Abstract] [Full Text] [Related]
3. [Chemotherapy of malignant gynecological tumor--arterial infusion and biological response modifiers(BRM)].
Fujiwara S; Akiya K
Nihon Sanka Fujinka Gakkai Zasshi; 1983 Nov; 35(11):2025-30. PubMed ID: 6663134
[No Abstract] [Full Text] [Related]
4. Experience gained in immunotherapy from the immunopharmacology of BCG leading to a second generation of systemic immunity adjuvants.
Mathe G
Comp Immunol Microbiol Infect Dis; 1980; 3(4):407-32. PubMed ID: 6451350
[No Abstract] [Full Text] [Related]
5. Immunotherapy of human cancer.
Hersh EM; Gutterman JU; Mavligit GM
Adv Intern Med; 1977; 22():145-85. PubMed ID: 65906
[No Abstract] [Full Text] [Related]
6. [Treatment of tumors of the urinary bladder with so-called immunopotentiators].
Tsujimura S; Kato J; Ueda K; Ohtaguro K
Hinyokika Kiyo; 1983 Jan; 29(1):9-15. PubMed ID: 6677093
[TBL] [Abstract][Full Text] [Related]
7. [Immunostimulant therapy of kidney diseases].
Karastanev I
Vutr Boles; 1982; 21(3):8-13. PubMed ID: 6180558
[No Abstract] [Full Text] [Related]
8. [Clinical efficacy of intratumoral administration of BRM in advanced cancer and their mechanism of actions].
Kuninobu H; Toge T; Takayama T; Baba N; Kegoya Y; Yanagawa E
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2769-73. PubMed ID: 2782888
[TBL] [Abstract][Full Text] [Related]
9. [BRM in the treatment of cancer].
Takaku F
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1597-602. PubMed ID: 2454612
[TBL] [Abstract][Full Text] [Related]
10. Biological response modifiers and their promise in clinical medicine.
Attallah AM; Yeatman TJ; Johnson RP; Petricciani JC
Pharmacol Ther; 1982; 19(3):435-54. PubMed ID: 6201933
[No Abstract] [Full Text] [Related]
11. Biological response modifiers: preclinical evaluation and clinical activity.
Smalley RV; Oldham RK
Crit Rev Oncol Hematol; 1984; 1(3):259-94. PubMed ID: 6085037
[TBL] [Abstract][Full Text] [Related]
12. [Significance of immunotherapy as an adjunct to surgical treatment in non-small cell carcinoma of the lung].
Fujisawa T
Gan To Kagaku Ryoho; 1985 Jan; 12(1):13-20. PubMed ID: 2981513
[TBL] [Abstract][Full Text] [Related]
13. [Immunostimulants--therapeutic aspects].
Diezel W; Volk HD; Daniel V; Gruner S; Sönnichsen N
Arch Geschwulstforsch; 1989; 59(1):45-51. PubMed ID: 2493778
[TBL] [Abstract][Full Text] [Related]
14. [Current therapy: immunopharmaceuticals].
Mahrle G
Z Hautkr; 1987 May; 62(10):753-6, 759-62, 765. PubMed ID: 2887076
[TBL] [Abstract][Full Text] [Related]
15. [Experimental studies on specific active immunotherapy using immune response of irradiated tumor tissues. 5. A combined effect of the immune response of cryopreserved tissue and OK-432].
Ogawa Y; Imanaka K; Gose K; Imajo Y; Kimura S
Nihon Gan Chiryo Gakkai Shi; 1982 Aug; 17(5):1305-10. PubMed ID: 7153622
[No Abstract] [Full Text] [Related]
16. [Immunotherapy with bestatin for acute non-lymphocytic leukemia (ANLL) in adults].
Kurita S; Ota K; Yamada K; Massaoka T; Uzuka Y; Ogawa N
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2742-50. PubMed ID: 6508324
[TBL] [Abstract][Full Text] [Related]
17. Biological response modifiers: their potential and limitations in cancer therapeutics.
Mihich E
Cancer Invest; 1985; 3(1):71-83. PubMed ID: 2578860
[No Abstract] [Full Text] [Related]
18. [The immunomodulating action of bestatin in the combined therapy of bladder cancer patients].
Neprina GS; Panteleeva ES; Vatin OE; Kariakin OB
Urol Nefrol (Mosk); 1994; (2):34-8. PubMed ID: 8017004
[TBL] [Abstract][Full Text] [Related]
19. [Experimental studies on specific active immunotherapy using immune responses of irradiated tumor tissue. 4. Effects of a combined use of a non-specific immunopotentiator, OK-432].
Imanaka K; Ogawa Y; Gose K; Imajo Y; Kimura S
Nihon Gan Chiryo Gakkai Shi; 1982 Aug; 17(5):1299-304. PubMed ID: 7153621
[No Abstract] [Full Text] [Related]
20. Immunopharmacologic bases of immunotherapy.
Hadden JW; Keskiner Merriam L
Clin Physiol Biochem; 1985; 3(2-3):111-9. PubMed ID: 2408810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
